Literature DB >> 17305985

Medullary thyroid carcinoma: a 20-year experience from a centre in South India.

Philip Finny1, Jubbin J Jacob, Nihal Thomas, Jim Philip, Simon Rajarathnam, Regi Oommen, Aravindan Nair, Mandalam S Seshadri.   

Abstract

BACKGROUND: Management of medullary thyroid carcinoma (MTC) remains controversial despite many advances over the past five decades. We attempt to review the presentation, management and prognosis of MTC at our institution over the last two decades.
METHODS: We conducted a retrospective review of the records of 40 patients with MTC over a period of 20 years.
RESULTS: Ten patients had hereditary MTC and 30 had sporadic MTC. The mean age of presentation was 41 years. Sixty-five per cent of the patients had a definite thyroid swelling and 43% had lymphadenopathy at the time of presentation. Total thyroidectomy with a central neck dissection was carried out in 82.5% of patients. Adjuvant therapy was given in 75% of patients because of extensive/residual disease. Postoperative hypercalcitoninaemia was seen 73% of patients. (131)I metaiodobenzylguanidine scanning was carried out in 16 patients with persistent hypercalcitoninaemia; the uptake was positive in 10 and negative in 6, indicating a positivity of 62%.
CONCLUSION: Medullary thyroid carcinoma accounts for 2.5% of thyroid carcinomas. There is a small male preponderance. In our series (131)I metaiodobenzylguanidine scan had a better positivity than what has been reported in the published work. Persistent postoperative hypercalcitoninaemia was associated with a poorer prognosis that did not reach statistical significant.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17305985     DOI: 10.1111/j.1445-2197.2006.03992.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  5 in total

1.  Outcome of Treatment for Medullary Thyroid Carcinoma-a Single Centre Experience.

Authors:  Anish Jacob Cherian; Pooja Ramakant; Rekha Pai; Marie Therese Manipadam; S Elanthenral; Anuradha Chandramohan; Julie Hephzibah; David Mathew; Dhukabandhu Naik; Thomas V Paul; Simon Rajaratnam; Nihal Thomas; M J Paul; Deepak Thomas Abraham
Journal:  Indian J Surg Oncol       Date:  2017-12-08

2.  Medullary thyroid cancer: clinico-pathological profile and outcome in a tertiary care center in North India.

Authors:  Prateek Kumar Mehrotra; Anjali Mishra; Saroj Kanta Mishra; Gaurav Agarwal; Amit Agarwal; Ashok Kumar Verma
Journal:  World J Surg       Date:  2011-06       Impact factor: 3.352

3.  Medullary Thyroid Cancer: An Experience from a Tertiary Care Hospital of a Developing Country.

Authors:  Sajjad A Khan; Abdul Aziz; Umer A Esbhani; Muhammad Q Masood
Journal:  Indian J Endocrinol Metab       Date:  2022-04-27

4.  RET mutations in a large indian family with medullary thyroid carcinoma.

Authors:  D M Mahesh; Arun G Nehru; M S Seshadri; Nihal Thomas; Aravindan Nair; Rekha Pai; Simon Rajaratnam
Journal:  Indian J Endocrinol Metab       Date:  2014-07

5.  Hereditary medullary thyroid carcinoma syndromes: experience from western India.

Authors:  Chakra Diwaker; Vijaya Sarathi; Sanjeet Kumar Jaiswal; Ravikumar Shah; Anuja Deshmukh; Anand Ebin Thomas; Gagan Prakash; Gaurav Malhotra; Virendra Patil; Anurag Lila; Nalini Shah; Tushar Bandgar
Journal:  Fam Cancer       Date:  2021-01-04       Impact factor: 2.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.